Provided by Tiger Fintech (Singapore) Pte. Ltd.

Biogen

116.49
-2.1200-1.79%
Pre-market: 117.721.23+1.06%06:35 EDT
Volume:1.76M
Turnover:204.96M
Market Cap:17.05B
PE:10.42
High:118.61
Open:117.97
Low:115.45
Close:118.61
Loading ...

RBC Trims Price Target on Biogen to $221 From $225, Keeps Outperform Rating

MT Newswires Live
·
03 Apr

Biopharma Credit Plc - Receives $8.25 Million Settlement Payment From Biogen

THOMSON REUTERS
·
02 Apr

Biogen's BIIB080 Gets FDA Fast-Track Designation in Alzheimer's Disease

Dow Jones
·
02 Apr

Biogen Says Investigational Alzheimer's Drug Receives FDA Fast Track Designation

MT Newswires Live
·
02 Apr

BRIEF-Biogen’S Investigational Tau-Targeting Therapy Biib080 Receives FDA Fast Track Designation For The Treatment Of Alzheimer’S Disease

Reuters
·
02 Apr

Biogen’s Investigational Tau-Targeting Therapy Biib080 Receives FDA Fast Track Designation for the Treatment of Alzheimer’s Disease

THOMSON REUTERS
·
02 Apr

Biogen: Phase 2 Celia Study Is NOW Fully Enrolled, With a Data Readout Expected in 2026

THOMSON REUTERS
·
02 Apr

Biogen’s Investigational Tau-Targeting Therapy BIIB080 Receives FDA Fast Track Designation for the Treatment of Alzheimer’s Disease

GlobeNewswire
·
02 Apr

BUZZ - Nasdaq top and bottom performing stocks at about 02:45 p.m. EDT on 2025-04-01

Reuters
·
02 Apr

Organon Acquires Tofidence for Intravenous Infusion in US

MT Newswires Live
·
01 Apr

Organon & Co - to Pay Tiered Royalties and Milestone Payments to Biogen

THOMSON REUTERS
·
01 Apr

Biogen (NASDAQ:BIIB) sheds US$697m, company earnings and investor returns have been trending downwards for past five years

Simply Wall St.
·
01 Apr

Biogen - Final Process for Ec Decision on Lecanemab’s Marketing Authorisation Application Underway

THOMSON REUTERS
·
01 Apr

Biogen Inc. Stock Underperforms Monday When Compared To Competitors

Dow Jones
·
01 Apr

Is the Future Bleak for SAVA Stock Following Another Setback?

Zacks
·
31 Mar

Biogen Inc. Stock Underperforms Friday When Compared To Competitors

Dow Jones
·
29 Mar

Biogen’s Favorable Outlook: Navigating Regulatory Challenges and Safety Advantages Justify Buy Rating

TIPRANKS
·
28 Mar

EU medicines regulator rejects Eli Lilly's Alzheimer's drug

Reuters
·
28 Mar

Lilly adds Alzheimer's to online offerings

Reuters
·
27 Mar

IONS Out-Licenses ex-U.S. Rights for Rare Disease Drug Tryngolza to Sobi

Zacks
·
27 Mar